people with narcolepsy for people with narcolepsy logo
Join

Welcome to the
PWN4PWN Newsroom

Your source for the latest updates, announcements, and media coverage about our work and the evolving world of narcolepsy and idiopathic hypersomnia.

Woman smiling in newsroom

PWN4PWN Latest Updates

News From around the Community

10/22/2025

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

09/16/2025

PWN4PWN Partners with Narcolepsy Life Academy to Reignite Health & Wellness 360 with Rise Up Program

09/16/2025

PWN4PWN and Udemy Partner to Expand Career Pathways for People with Narcolepsy & Idiopathic Hypersomnia

09/16/2025

PWN4PWN and TSA Partner to Launch Toolkit Supporting Travelers with Narcolepsy and Cataplexy — First Step in Larger Accessibility Roadmap

09/10/2025

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

09/10/2025

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

09/08/2025

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

07/25/2025

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Older News

12/25/24

HCPlive Sleep Medicine Year in Review: 2024

09/25/24

AVADEL Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate)

09/27/24

CENTESSA Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 Agonist, at the 27th Congress of the European Sleep Research Society

09/03/24

PWN4PWN Welcomes Kyle Chastain as New Treasurer on Board of Directors

07/31/24

AVADEL Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

06/03/24

TAKEDA Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

02/21/24

Harmony Biosciences U.S. Food and Drug Administration has granted priority review for Harmony Biosciences’ application for WAKIX® (pitolisant) in pediatric narcolepsy

01/24/24

Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing